Data from Master Clinical Trials—focused on transforming care for patients with acute myeloid leukemia—will be presented at ...

Baker, who is based in the United Kingdom, recently sat down for an interview with CURE alongside Dr. Marina Kremyanskaya, ...

Stage 1 PV management includes phlebotomy, low-dose aspirin, cytoreductive therapy, and lifestyle changes to prevent complications. Stage 1 polycythemia vera is manageable with monitoring, phlebotomy, ...

Dana-Farber Cancer Institute will present more than 120 oral and poster presentations at the 67th American Society for ...

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell ...

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...

Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN).BPDCN is a highly aggressive, orphan he ...

Ding, X.F., Wang, J.L., Shi, A.Q., et al. (2021) Nasal Septal Schwannoma: A Case Report. Journal of China Clinic Medical Imaging, 32, 226-227. Mey, K.H., Buchwald, C., Daugaard, S. and Prause, J.U.

A highly specialized and multidisciplinary intervention was performed at the Sant'Anna and San Sebastiano Hospital in Caserta ...

Fine-needle aspiration cytology, carried out in 10 patients, suggested the presence of a phyllodes breast tumor in 8 cases.

HLA compatibility is considered the key criterion for selecting donors for allo-HSCT. DKMS study data presented at the DGHO ...

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy classified by WHO and marked by cutaneous lesions, bone marrow infiltration, and CNS involvement.